Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	New Amedeo service: Amedeo COVID-19 (formerly 2019-nCoV) Weekly publication summary

Prostate Cancer

Free Subscription 01.01.2020 4 AJR Am J Roentgenol 2 BJU Int 2 BMC Cancer 5 BMC Urol 1 Br J Cancer 2 Cancer 1 Cancer Imaging 3 Cancer Lett 1 Cancer Res 2 Clin Cancer Res 1 Endocrinology 1 Eur J Radiol 6 Eur Urol 1 Int J Cancer 5 Int J Radiat Oncol Biol Phys 1 Invest Radiol 4 J Clin Oncol 1 J Nucl Med 1 J Surg Oncol 15 J Urol 2 N Engl J Med 1 Nat Rev Urol 2 Oncol Rep 1 PLoS Med 3 PLoS One 4 Prostate 1 Radiology 2 Urol Int

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

AJR Am J Roentgenol

1. TANAKA T, Froemming AT, Panda A, Edmonson HA, et al
   Safety and Image Quality of 1.5-T Endorectal Coil Multiparametric MRI of the Prostate or Prostatectomy Fossa for Patients With Pacemaker or Implantable Cardioverter-Defibrillator.
   AJR Am J Roentgenol. 2019 Jan 30:1-8. doi: 10.2214/AJR.18.20266.
   PubMed     Text format     Abstract available
   
   
2. HOTKER AM, Dappa E, Mazaheri Y, Ehdaie B, et al
   The Influence of Background Signal Intensity Changes on Cancer Detection in Prostate MRI.
   AJR Am J Roentgenol. 2019 Feb 4:1-7. doi: 10.2214/AJR.18.20295.
   PubMed     Text format     Abstract available
   
   
3. BARKOVICH EJ, Shankar PR, Westphalen AC
   A Systematic Review of the Existing Prostate Imaging Reporting and Data System Version 2 (PI-RADSv2) Literature and Subset Meta-Analysis of PI-RADSv2 Categories Stratified by Gleason Scores.
   AJR Am J Roentgenol. 2019 Feb 26:1-8. doi: 10.2214/AJR.18.20571.
   PubMed     Text format     Abstract available
   
   
4. FREIFELD Y, Diaz de Leon A, Xi Y, Pedrosa I, et al
   Diagnostic Performance of Prospectively Assigned Likert Scale Scores to Determine Extraprostatic Extension and Seminal Vesicle Invasion With Multiparametric MRI of the Prostate.
   AJR Am J Roentgenol. 2018 Dec 27:1-6. doi: 10.2214/AJR.18.20320.
   PubMed     Text format     Abstract available
   
   

   
   BJU Int

5. HERLEMANN A, Meng MV
   Editorial: Conversion to negative surgical margin after intraoperative frozen section - (un)necessary effort and relevance in 2019?
   BJU Int. 2019;123:744-746.
   PubMed     Text format    
   
   
6. UEMURA H, Ye D, Kanesvaran R, Chiong E, et al
   United in Fight against prOstate cancer registry (UFO): first results from a large, multi-centre, prospective, longitudinal cohort study of advanced prostate cancer in Asia.
   BJU Int. 2019 Dec 23. doi: 10.1111/bju.14980.
   PubMed     Text format     Abstract available
   
   

   
   BMC Cancer

7. ZONI E, Minoli M, Bovet C, Wehrhan A, et al
   Preoperative plasma fatty acid metabolites inform risk of prostate cancer progression and may be used for personalized patient stratification.
   BMC Cancer. 2019;19:1216.
   PubMed     Text format     Abstract available
   
   
8. ZHEN L, Liu X, Yegang C, Yongjiao Y, et al
   Accuracy of multiparametric magnetic resonance imaging for diagnosing prostate Cancer: a systematic review and meta-analysis.
   BMC Cancer. 2019;19:1244.
   PubMed     Text format     Abstract available
   
   

   
   BMC Urol

9. HINATA N, Bando Y, Chiba K, Furukawa J, et al
   Application of hyaluronic acid/carboxymethyl cellulose membrane for early continence after nerve-sparing robot-assisted radical prostatectomy.
   BMC Urol. 2019;19:25.
   PubMed     Text format     Abstract available
   
   
10. WANG X, Wu Y, Guo J, Chen H, et al
    Oncological safety of intrafascial nerve-sparing radical prostatectomy compared with conventional process: a pooled review and meta-regression analysis based on available studies.
    BMC Urol. 2019;19:41.
    PubMed     Text format     Abstract available
    
    
11. KOSKAS Y, Lannes F, Branger N, Giusiano S, et al
    Extent of positive surgical margins following radical prostatectomy: impact on biochemical recurrence with long-term follow-up.
    BMC Urol. 2019;19:37.
    PubMed     Text format     Abstract available
    
    
12. BOCK D, Angenete E, Bjartell A, Hugosson J, et al
    Agreement between patient reported outcomes and clinical reports after radical prostatectomy - a prospective longitudinal study.
    BMC Urol. 2019;19:35.
    PubMed     Text format     Abstract available
    
    
13. BORGES RC, Tobias-Machado M, Gabriotti EN, Dos Santos Figueiredo FW, et al
    Post-radical prostatectomy urinary incontinence: is there any discrepancy between medical reports and patients' perceptions?
    BMC Urol. 2019;19:32.
    PubMed     Text format     Abstract available
    
    

    
    Br J Cancer

14. RUSHWORTH LK, Hewit K, Munnings-Tomes S, Somani S, et al
    Repurposing screen identifies mebendazole as a clinical candidate to synergise with docetaxel for prostate cancer treatment.
    Br J Cancer. 2019 Dec 17. pii: 10.1038/s41416-019-0681.
    PubMed     Text format     Abstract available
    
    

    
    Cancer

15. SAAD AM, Gad MM, Al-Husseini MJ, AlKhayat MA, et al
    Suicidal death within a year of a cancer diagnosis: A population-based study.
    Cancer. 2019;125:972-979.
    PubMed     Text format     Abstract available
    
    
16. CORRIGAN KL, Wall KC, Bartlett JA, Suneja G, et al
    Cancer disparities in people with human immunodeficiency virus: A systematic review of screening for non-AIDS-defining malignancies.
    Cancer. 2019 Jan 15. doi: 10.1002/cncr.31838.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Imaging

17. XU L, Zhang G, Shi B, Liu Y, et al
    Comparison of biparametric and multiparametric MRI in the diagnosis of prostate cancer.
    Cancer Imaging. 2019;19:90.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Lett

18. RAY J, Haughey C, Hoey C, Jeon J, et al
    miR-191 promotes radiation resistance of prostate cancer through interaction with RXRA.
    Cancer Lett. 2019 Dec 21. pii: S0304-3835(19)30639.
    PubMed     Text format     Abstract available
    
    
19. YANG Z, Chen J, Xie H, Liu T, et al
    Androgen receptor suppresses prostate cancer metastasis but promotes bladder cancer metastasis via differentially altering miRNA525-5p/SLPI-mediated vasculogenic mimicry formation.
    Cancer Lett. 2019 Dec 13. pii: S0304-3835(19)30624.
    PubMed     Text format     Abstract available
    
    
20. XU H, Sun Y, You B, Huang CP, et al
    Androgen receptor reverses the oncometabolite R-2-hydroxyglutarate-induced prostate cancer cell invasion via suppressing the circRNA-51217/miRNA-646/TGFbeta1/p-Smad2/3 signaling.
    Cancer Lett. 2019 Dec 14. pii: S0304-3835(19)30620.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Res

21. LIU C, Gao AC
    IFNgamma, a Double-Edged Sword in Cancer Immunity and Metastasis.
    Cancer Res. 2019;79:1032-1033.
    PubMed     Text format     Abstract available
    
    

    
    Clin Cancer Res

22. DEHM SM, Montgomery B, Plymate SR
    AR-Variant-Positive CTC: A Surrogate for a Surrogate for Taxane Therapy Outcome?
    Clin Cancer Res. 2019;25:1696-1698.
    PubMed     Text format     Abstract available
    
    
23. REBELLO RJ, Oing C, Gillessen S, Bristow RG, et al
    TP53 and Prognosis in mCRPC Survival: Biology or Coincidence?
    Clin Cancer Res. 2019;25:1699-1701.
    PubMed     Text format     Abstract available
    
    

    
    Endocrinology

24. BLUNDON MA, Dasgupta S
    Metabolic Dysregulation Controls Endocrine Therapy-Resistant Cancer Recurrence and Metastasis.
    Endocrinology. 2019;160:1811-1820.
    PubMed     Text format     Abstract available
    
    

    
    Eur J Radiol

25. CRISTEL G, Esposito A, Damascelli A, Briganti A, et al
    Can DCE-MRI reduce the number of PI-RADS v.2 false positive findings? Role of quantitative pharmacokinetic parameters in prostate lesions characterization.
    Eur J Radiol. 2019;118:51-57.
    PubMed     Text format     Abstract available
    
    

    
    Eur Urol

26. SINGH K, Tin AL, Dunn RL, Kim T, et al
    Development and Validation of Crosswalks for Patient-reported Sexual and Urinary Outcomes Between Commonly Used Instruments.
    Eur Urol. 2019;75:723-730.
    PubMed     Text format     Abstract available
    
    
27. MATSUBARA N, Chi KN, Ozguroglu M, Rodriguez-Antolin A, et al
    Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Depriv
    Eur Urol. 2019 Dec 13. pii: S0302-2838(19)30894.
    PubMed     Text format     Abstract available
    
    
28. PATASIUS A, Smailyte G
    Re: MaryBeth B. Culp, Isabelle Soerjomataram, Jason A. Efstathiou, Freddie Bray, Ahmedin Jemal. Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.08.005.
    Eur Urol. 2019 Dec 13. pii: S0302-2838(19)30908.
    PubMed     Text format    
    
    
29. CHESNUT GT, Vertosick EA, Benfante N, Sjoberg DD, et al
    Role of Changes in Magnetic Resonance Imaging or Clinical Stage in Evaluation of Disease Progression for Men with Prostate Cancer on Active Surveillance.
    Eur Urol. 2019 Dec 21. pii: S0302-2838(19)30948.
    PubMed     Text format     Abstract available
    
    
30. TODENHOFER T, Gratzke C
    Re: Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer.
    Eur Urol. 2019 Dec 21. pii: S0302-2838(19)30956.
    PubMed     Text format    
    
    
31. SLOVIN SF
    Chimeric Antigen Receptor T-cell Therapy in Prostate Cancer: Reality or Folly?
    Eur Urol. 2019 Dec 18. pii: S0302-2838(19)30910.
    PubMed     Text format    
    
    

    
    Int J Cancer

32. ERSVAER E, Hveem TS, Vlatkovic L, Brennhovd B, et al
    Prognostic value of DNA ploidy and automated assessment of stroma fraction in prostate cancer.
    Int J Cancer. 2019 Dec 17. doi: 10.1002/ijc.32832.
    PubMed     Text format     Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

33. JULIET VAN SON M, Peters M, Moerland MA, van der Voort van Zyp JRN, et al
    In Reply to David and Kamrava.
    Int J Radiat Oncol Biol Phys. 2019;104:1183-1184.
    PubMed     Text format    
    
    
34. DAVID J, Kamrava M
    In Regard to Peters et al.
    Int J Radiat Oncol Biol Phys. 2019;104:1182-1183.
    PubMed     Text format    
    
    
35. MORTON GC, Hoskin PJ
    Single Fraction High-Dose-Rate Brachytherapy: Too Good to Be True?
    Int J Radiat Oncol Biol Phys. 2019;104:1054-1056.
    PubMed     Text format    
    
    
36. PASALIC D, Kuban DA, Allen PK, Tang C, et al
    Dose Escalation for Prostate Adenocarcinoma: A Long-Term Update on the Outcomes of a Phase 3, Single Institution Randomized Clinical Trial.
    Int J Radiat Oncol Biol Phys. 2019;104:790-797.
    PubMed     Text format     Abstract available
    
    
37. LIU C, Gardner SJ, Wen N, Elshaikh MA, et al
    Automatic Segmentation of the Prostate on CT Images Using Deep Neural Networks (DNN).
    Int J Radiat Oncol Biol Phys. 2019;104:924-932.
    PubMed     Text format     Abstract available
    
    

    
    Invest Radiol

38. AKSIT CIRIS P, Chiou JG, Glazer DI, Chao TC, et al
    Accelerated Segmented Diffusion-Weighted Prostate Imaging for Higher Resolution, Higher Geometric Fidelity, and Multi-b Perfusion Estimation.
    Invest Radiol. 2019;54:238-246.
    PubMed     Text format     Abstract available
    
    

    
    J Clin Oncol

39. SLOVIN SF
    Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer: Can an Agnostic Become a Believer?
    J Clin Oncol. 2019 Dec 26:JCO1902921. doi: 10.1200/JCO.19.02921.
    PubMed     Text format    
    
    
40. AGGARWAL R, Huang J, Alumkal J, Feng FY, et al
    Reply to A. Dalla Volta et al.
    J Clin Oncol. 2019;37:351-352.
    PubMed     Text format    
    
    
41. VOLTA AD, Cosentini D, Antonelli A, Pedersini R, et al
    Transformation of Prostate Adenocarcinoma Into Small-Cell Neuroendocrine Cancer Under Androgen Deprivation Therapy: Much Is Achieved But More Information Is Needed.
    J Clin Oncol. 2019;37:350-351.
    PubMed     Text format    
    
    
42. MARTIN J, Lukka H, Catton C
    Reply to J. David et al.
    J Clin Oncol. 2019;37:441.
    PubMed     Text format    
    
    

    
    J Nucl Med

43. MICHAUD L, Touijer K, Mauguen A, Zelefsky M, et al
    (11)C-choline PET/CT in recurrent prostate cancer: retrospective analysis in a large US patient series.
    J Nucl Med. 2019 Dec 20. pii: jnumed.119.233098. doi: 10.2967/jnumed.119.233098.
    PubMed     Text format     Abstract available
    
    

    
    J Surg Oncol

44. KIERKEGAARD P, Vale MD, Garrison S, Hollenbeck BK, et al
    Mechanisms of decision-making in preoperative assessment for older adult prostate cancer patients-A qualitative study.
    J Surg Oncol. 2019 Dec 23. doi: 10.1002/jso.25819.
    PubMed     Text format     Abstract available
    
    

    
    J Urol

45. KORNBERG Z, Cooperberg MR, Cowan JE, Chan JM, et al
    A 17-Gene Genomic Prostate Score as a Predictor of Adverse Pathology in Men on Active Surveillance.
    J Urol. 2019;202:702-709.
    PubMed     Text format     Abstract available
    
    
46. LOVEGROVE CE, Miah S, El-Shater Bosaily A, Bott S, et al
    Comparison of Transrectal Ultrasound Biopsy to Transperineal Template Mapping Biopsies Stratified by Multiparametric Magnetic Resonance Imaging Score in the PROMIS Trial.
    J Urol. 2020;203:100-107.
    PubMed     Text format     Abstract available
    
    
47. LEE J, Kim HY, Goh HJ, Heo JE, et al
    Retzius Sparing Robot-Assisted Radical Prostatectomy Conveys Early Regain of Continence over Conventional Robot-Assisted Radical Prostatectomy: A Propensity Score Matched Analysis of 1,863 Patients.
    J Urol. 2020;203:137-144.
    PubMed     Text format     Abstract available
    
    
48. XU J, Helfand BT
    Editorial Comment.
    J Urol. 2020;203:80-81.
    PubMed     Text format    
    
    
49. LOEB S, Cazzaniga W, Robinson D, Garmo H, et al
    Opioid Use after Radical Prostatectomy: Nationwide, Population Based Study in Sweden.
    J Urol. 2020;203:145-150.
    PubMed     Text format     Abstract available
    
    
50. HAMILTON RJ
    Editorial Comment.
    J Urol. 2020;203:126-127.
    PubMed     Text format    
    
    
51. EMMETT L, Hofman MS
    Editorial Comment.
    J Urol. 2020;203:99.
    PubMed     Text format    
    
    
52. TANEJA SS
    Re: Gold Nanoshell-Localized Photothermal Ablation of Prostate Tumors in a Clinical Pilot Device Study.
    J Urol. 2020;203:31.
    PubMed     Text format    
    
    
53. GULATI R, Etzioni R
    Re: Personalized Risks of Over Diagnosis for Screen Detected Prostate Cancer Incorporating Patient Comorbidities: Estimation and Communication.
    J Urol. 2019 Dec 17:101097JU0000000000000703. doi: 10.1097/JU.0000000000000703.
    PubMed     Text format    
    
    
54. SHAH N, Ioffe V
    Re: Personalized Risks of Over Diagnosis for Screen Detected Prostate Cancer Incorporating Patient Comorbidities: Estimation and Communication.
    J Urol. 2019 Dec 17:101097JU0000000000000702. doi: 10.1097/JU.0000000000000702.
    PubMed     Text format    
    
    
55. PAK S, Suh YS, Lee DE, Kim SH, et al
    Association Between Postoperative Detection of Circulating Tumor Cells and Recurrence in Patients with Prostate Cancer.
    J Urol. 2019 Dec 17:101097JU0000000000000704. doi: 10.1097/JU.0000000000000704.
    PubMed     Text format     Abstract available
    
    
56. CARLSSON S, Benfante N, Alvim R, Sjoberg DD, et al
    Long-Term Outcomes of Active Surveillance for Prostate Cancer - The Memorial Sloan Kettering Cancer Center Experience.
    J Urol. 2019 Dec 23:101097JU0000000000000713. doi: 10.1097/JU.0000000000000713.
    PubMed     Text format     Abstract available
    
    
57. FILSON CP
    Editorial Comment.
    J Urol. 2020;203:135.
    PubMed     Text format    
    
    
58. TODENHOFER T
    Editorial Comment.
    J Urol. 2020;203:81.
    PubMed     Text format    
    
    
59. ZAMBRANO IA, Tan HJ
    Editorial Comment.
    J Urol. 2020;203:135-136.
    PubMed     Text format    
    
    

    
    N Engl J Med

60. EISENBERGER MA, Antonarakis ES
    Hormonal Therapy or Chemotherapy for Metastatic Prostate Cancer - Playing the Right CARD.
    N Engl J Med. 2019;381:2564-2566.
    PubMed     Text format    
    
    
61. AL HUSSEIN AL AWAMLH B, Ma X, Christos P, Hu JC, et al
    Active Surveillance for Black Men with Low-Risk Prostate Cancer in the United States.
    N Engl J Med. 2019;381:2581-2582.
    PubMed     Text format    
    
    

    
    Nat Rev Urol

62. SCHMID S, Omlin A
    Progress in therapy across the spectrum of advanced prostate cancer.
    Nat Rev Urol. 2019 Dec 16. pii: 10.1038/s41585-019-0270.
    PubMed     Text format    
    
    

    
    Oncol Rep

63. MARTINS CA, Rocha GDG, Gattass CR, Takiya CM, et al
    Pomolic acid exhibits anticancer potential against a docetaxelresistant PC3 prostate cell line.
    Oncol Rep. 2019;42:328-338.
    PubMed     Text format     Abstract available
    
    
64. KAMINSKA K, Bialkowska A, Kowalewski J, Huang S, et al
    Differential gene methylation patterns in cancerous and noncancerous cells.
    Oncol Rep. 2019;42:43-54.
    PubMed     Text format     Abstract available
    
    

    
    PLoS Med

65. CALLENDER T, Emberton M, Morris S, Eeles R, et al
    Polygenic risk-tailored screening for prostate cancer: A benefit-harm and cost-effectiveness modelling study.
    PLoS Med. 2019;16:e1002998.
    PubMed     Text format     Abstract available
    
    

    
    PLoS One

66. COSMA I, Tennstedt-Schenk C, Winzler S, Psychogios MN, et al
    The role of gadolinium in magnetic resonance imaging for early prostate cancer diagnosis: A diagnostic accuracy study.
    PLoS One. 2019;14:e0227031.
    PubMed     Text format     Abstract available
    
    
67. ZHANG H, Gordon R, Li W, Yang X, et al
    Genistein treatment duration effects biomarkers of cell motility in human prostate.
    PLoS One. 2019;14:e0214078.
    PubMed     Text format     Abstract available
    
    
68. BEER L, Polanec SH, Baltzer PAT, Schatzl G, et al
    4D perfusion CT of prostate cancer for image-guided radiotherapy planning: A proof of concept study.
    PLoS One. 2019;14:e0225673.
    PubMed     Text format     Abstract available
    
    

    
    Prostate

69. CHEN X, Liu J, Cheng L, Li C, et al
    Inhibition of noncanonical Wnt pathway overcomes enzalutamide resistance in castration-resistant prostate cancer.
    Prostate. 2019 Dec 19. doi: 10.1002/pros.23939.
    PubMed     Text format     Abstract available
    
    
70. HOSSAIN A, Arimura H, Kinoshita F, Ninomiya K, et al
    Automated approach for estimation of grade groups for prostate cancer based on histological image feature analysis.
    Prostate. 2019 Dec 23. doi: 10.1002/pros.23943.
    PubMed     Text format     Abstract available
    
    
71. MOLLARD P, Perrot E, Blanchet P, Brureau L, et al
    Overall, specific, and metastasis-free survival of Afro-Caribbean men with pathological Gleason 6 prostate cancer.
    Prostate. 2019 Dec 23. doi: 10.1002/pros.23947.
    PubMed     Text format     Abstract available
    
    
72. KATO M, Hirakawa A, Kobayashi Y, Yamamoto A, et al
    Response of intraductal carcinoma of the prostate to androgen deprivation therapy predicts prostate cancer prognosis in radical prostatectomy patients.
    Prostate. 2019 Dec 20. doi: 10.1002/pros.23942.
    PubMed     Text format     Abstract available
    
    

    
    Radiology

73. ZHANG M, Milot L, Khalvati F, Sugar L, et al
    Value of Increasing Biopsy Cores per Target with Cognitive MRI-targeted Transrectal US Prostate Biopsy.
    Radiology. 2019 Jan 29:180712. doi: 10.1148/radiol.2019180712.
    PubMed     Text format     Abstract available
    
    

    
    Urol Int

74. MOSCHINI M, Zamboni S, Mattei A, Baumeister P, et al
    Radical Cystectomy in Pathological T4a and T4b Bladder Cancer Patients: Is There Any Space for Sub Stratification?
    Urol Int. 2019 Jan 29:1-8. doi: 10.1159/000493899.
    PubMed     Text format     Abstract available
    
    
75. MEISSNER VH, Bittner R, Kron M, Schiele S, et al
    Impact of a Changing Population Structure and Clustering of Cancer in Prostate Cancer Patients Depending on a First-Degree Family History.
    Urol Int. 2019 Dec 20:1-8. doi: 10.1159/000504789.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: